Kruder, who serves as CEO of both Paramount Health Rx and Alpha BioMed Industries, argues that the upcoming federal review serves as a critical junction for standardizing how patients access personalized care. His companies currently operate a nationwide network connecting patients with licensed prescribers and 503A compounding pharmacies, a model he claims is essential for shifting the healthcare industry toward a prevention-first framework.
Trevor Kruder Seeks to Shape Peptide Regulation Ahead of FDA Review
With the FDA Pharmacy Compounding Advisory Committee scheduled to meet July 23-24, 2026, to weigh the future of peptide inclusion on the 503A Bulk Drug Substances List, industry executive Trevor Kruder is positioning himself as a key voice on the intersection of regulatory compliance and patient-directed telehealth access.
The committee’s deliberations will determine whether specific peptides move forward under current regulatory pathways. According to Kruder, the goal is to balance stringent safety protocols with the expansion of lawful, prescriber-directed care. He maintains that establishing clear, evidence-based standards for domestic peptide manufacturing is the most effective way to ensure long-term patient safety while maintaining access to personalized treatment options. Kruder is positioning his firms to support these compliant pathways as the agency reassesses the current landscape.
Comments (0)
No comments yet. Be the first!